MXPA02007514A - Compuestos novedosos de difeniletileno. - Google Patents

Compuestos novedosos de difeniletileno.

Info

Publication number
MXPA02007514A
MXPA02007514A MXPA02007514A MXPA02007514A MXPA02007514A MX PA02007514 A MXPA02007514 A MX PA02007514A MX PA02007514 A MXPA02007514 A MX PA02007514A MX PA02007514 A MXPA02007514 A MX PA02007514A MX PA02007514 A MXPA02007514 A MX PA02007514A
Authority
MX
Mexico
Prior art keywords
compounds
diphenylethylene compounds
novel
glucose
novel diphenylethylene
Prior art date
Application number
MXPA02007514A
Other languages
English (en)
Inventor
Debendranath Dey
Original Assignee
Calyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/642,618 external-priority patent/US6624197B1/en
Application filed by Calyx Therapeutics Inc filed Critical Calyx Therapeutics Inc
Publication of MXPA02007514A publication Critical patent/MXPA02007514A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan los compuestos novedosos de difeniletileno que se administran oralmente para disminuir las concentraciones de circulacion de la glucosa. Tambien se muestra el efecto en la ratas resistentes a la insulina. Tambien se muestran los efectos sobre las concentraciones de lipido y leptina. Los compuestos son agentes anti-diabeticos oralmente efectivos que pueden normalizar el metabolismo de glucosa y lipido en sujetos con diabetes.
MXPA02007514A 2000-02-04 2001-02-05 Compuestos novedosos de difeniletileno. MXPA02007514A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18034000P 2000-02-04 2000-02-04
US09/642,618 US6624197B1 (en) 1998-05-08 2000-08-17 Diphenylethylene compounds
PCT/US2001/003797 WO2001056382A1 (en) 2000-02-04 2001-02-05 Novel diphenylethylene compounds

Publications (1)

Publication Number Publication Date
MXPA02007514A true MXPA02007514A (es) 2004-02-26

Family

ID=40157708

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02007514A MXPA02007514A (es) 2000-02-04 2001-02-05 Compuestos novedosos de difeniletileno.

Country Status (10)

Country Link
EP (1) EP1251738B1 (es)
JP (1) JP2003521500A (es)
CN (1) CN100484400C (es)
AT (1) ATE417503T1 (es)
AU (1) AU784974B2 (es)
CA (1) CA2397076A1 (es)
DE (1) DE60137020D1 (es)
MX (1) MXPA02007514A (es)
NZ (1) NZ520829A (es)
WO (1) WO2001056382A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790808C (en) 2003-04-22 2016-02-02 Novozymes Biologicals Holding A/S Use of lipo-chitooligosaccharides to initiate early flowering leading to increased flower numbers and increased yield in plants and related methods and compositions
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
CN1723884A (zh) * 2004-07-21 2006-01-25 中国人民解放军军事医学科学院放射医学研究所 顺式－1，2－取代的二苯乙烯衍生物用于制备治疗或预防糖尿病的药物的用途
EP2519100B1 (en) 2009-12-29 2017-03-15 Mapi Pharma Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
WO2024061362A1 (zh) * 2022-09-22 2024-03-28 中国科学院上海药物研究所 用于防治血管扩张性疾病的化合物及其制法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2524827A (en) * 1948-05-13 1950-10-10 Schering Corp Halogen substituted polycyclic aryl aliphatic acids
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
AU669279B2 (en) * 1993-03-10 1996-05-30 Morinaga Milk Industry Company Limited Stilbene derivative and stilbene analog derivative, and use thereof
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
JPH0959245A (ja) * 1995-08-25 1997-03-04 Yamanouchi Pharmaceut Co Ltd Ｎ−（２−プロペノイル）グアニジン誘導体
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
IL136605A0 (en) * 1998-03-31 2001-06-14 Warner Lambert Co Quinolones as serine protease inhibitors
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
MXPA01011760A (es) * 1999-05-18 2003-09-04 Calyx Therapeutics Inc Compuestos novedosos de difeniletileno.
US6413504B1 (en) * 2000-06-30 2002-07-02 Calyx Therapeutics, Inc. Alpha-arylated cinnamic esters and 1,4-bis(alpha-carboxyl-beta-styryl)benzene esters an UV-blocking agents

Also Published As

Publication number Publication date
EP1251738A4 (en) 2005-08-10
JP2003521500A (ja) 2003-07-15
CN1437441A (zh) 2003-08-20
NZ520829A (en) 2004-12-24
DE60137020D1 (de) 2009-01-29
CN100484400C (zh) 2009-05-06
AU784974B2 (en) 2006-08-10
WO2001056382A1 (en) 2001-08-09
EP1251738B1 (en) 2008-12-17
ATE417503T1 (de) 2009-01-15
EP1251738A1 (en) 2002-10-30
AU3333201A (en) 2001-08-14
CA2397076A1 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
Robert et al. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects
Osei Insulin resistance and systemic hypertension
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
BR9911656A (pt) Composição farmacêutica, processos para prevenção ou tratamento de diabetes em um mamìfero, para prevenção ou tratamento de complicações diabéticas em um mamìfero e para prevenção ou tratamento da tolerância a glicose prejudicada em um mamìfero, uso de um sensibilizador de insulina, e, proceso para reduzir os efeitos colaterais de um sensibilizador de insulina ou/ e um anorético administrado a um mamìfero diabético
Otte et al. Nicotinamide–biologic actions of an emerging cosmetic ingredient
WO2004080401A3 (en) Oral insulin therapies and protocol
PT1337236E (pt) Suplemento a ser administrado entericamente para alimentacao parenterica ou paraalimentacao parcial enterica/ oral de doentes em estado critico, doentes cronicos e de pessoas mal nutridas
Baysal et al. Is the combination of calcipotriol and PUVA effective in vitiligo?
WO2005012485A3 (en) Methods for treating diabetes and related disorders using pde10a inhibitors
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
WO2001062237A3 (en) Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
BRPI0408097A (pt) composição de insulina oral e processos para a produção e para o uso da mesma
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
CA2238465A1 (fr) Composes triaromatiques, compositions les contenant et utilisations
Ono et al. Plasma total glutathione concentrations in epileptic patients taking anticonvulsants
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
MXPA02007514A (es) Compuestos novedosos de difeniletileno.
Draelos The combination of 2% 4‐hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups
Cersosimo et al. Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes
Imamura et al. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes
MITCHELL Host susceptibility and acetaminophen liver injury
Monago et al. Effect of combined therapy of diabinese and nicotinic acid on liver enzymes in rabbits with dithizone-induced diabetes
Horikoshi et al. Punctate palmoplantar keratoderma with pigmentary lesions on the dorsa of feet and ankles: successful treatment with a combination of low‐dose oral etretinate and topical calcipotriol
FR2694694A1 (fr) Composition active pour le traitement du psoriasis, notamment le psoriasis du cuir chevelu.

Legal Events

Date Code Title Description
FG Grant or registration